Clinical Utility of Exome Sequencing: Post-Exome Testing Decision Changes in the Management of Children with Suspected Rare Genetic Disease.

Impact of first-tier exome sequencing on post-exome testing decision changes (P-TDC)

This Genetics in Medicine study quantifies exome sequencing clinical utility via a new metric: post-exome testing decision changes (P-TDC). Using a simulation model of 523 suspected rare genetic disease children, first-tier exome achieves a P-TDC of 0.94 versus 0.71 for conventional strategies, reducing unnecessary tests and improving diagnostic pathway efficiency.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Quantifying ES clinical utility beyond diagnostic yield is valuable for health economic evaluations. The P-TDC metric captures care decision impact — precisely the argument needed to justify first-tier exome access.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 7/10